References

1. Mangia, A et al. Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin. Aliment Pharmacol Ther.2010 jun 8 ;31(12): 1346-53. PubMed | Google Scholar


2. Ancel, D, et al. Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin. Eur J Gastroenterol Hepatol. 2009; 21(7): 726-9. PubMed | Google Scholar


3. Di Marco, V, et al. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood. 2010; 116(16): 2875-83. PubMed | Google Scholar


4. Hassan, M, et al. Hepatitis C virus in sickle cell disease. J Natl Med Assoc. 2003; 95(10): 939-42. PubMed | Google Scholar


5. DeVault, K,R, et al. Hepatitis C in sickle cell anemia. J Clin Gastroenterol. 1994; 18(3): 206-9. PubMed | Google Scholar


6. Ayyub, M,A, et al. Successful treatment of chronic hepatitis C virus infection with peginterferon alpha-2a and ribavirin in patients with sickle cell disease. Saudi Med J. 2009; 30(5): 712-6. PubMed | Google Scholar